Home
Search:
1146 feeds
357 categories
11368 articles (<24 hours)
1919 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


Valid HTML 4.01 Transitional

RSS FeedsINVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
(WorldNews Health)

 
 

14 november 2017 15:58:43

 
INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events
(WorldNews Health)
 




INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events Late-breaking study shows improved renal and heart failure outcomes also seen with INVOKANAin both of these patient groups RARITAN, N.J.and ANAHEIM, Calif.,November 14, 2017 - Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA (canagliflozin) demonstrated a reduced risk of cardiovascular (CV) outcomes in patients with and without a history of CV disease. INVOKANA also achieved similar and proportional risk reductions for hospitalization due to heart failure (HHF) and renal...
 
7 viewsCategory: Science > Medicine
 
No changes planned for Louisiana Medicaid deal extensions
(WorldNews Health)
Genworth 2017 Annual Cost of Care Survey: Home Health Care Costs Remained Flat in Colorado; Overall Costs Up
(WorldNews Health)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2017 Indigonet Services B.V.. Contact: Tim Hulsen
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn
Indigonet Services BV is not responsible for any incorrect or outdated information on this site.
If, however, you would like to see an article removed, you can send us an e-mail quoting the article number.